Natalia Martinez-Acuña

Natalia Martinez-Acuña


Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
7 July 2022 in Biosensors
Verified
Journal Article
Open access
PDF file
CMCynthia Martinez-Liu
Cynthia Martinez-Liu
CMCarlos Machain-Williams
Carlos Machain-Williams
NMNatalia Martinez-Acuña
Natalia Martinez-Acuña
SSSonia Lozano Sepulveda
Sonia Lozano Sepulveda
KGKame Galan-Huerta
Kame Galan-Huerta
ARAna M. Rivas-Estilla
Ana M. Rivas-Estilla
Flavivirus detection in humans and mosquito reservoirs has been an important issue since it can cause a variety of illnesses and could represent a health problem in geographical zones where the vector is endemic. In this work, we designed and characterized a biosensor based on gold nanoparticles (AuNPs) and antibody 4G2 for the detection of dengue virus (DENV) in vitro, obtaining different conjugates (with different antibody concentrations). The AuNP–4G2 conjugates at concentrations of 1, 3, and 6 µg/mL presented an increase in the average hydrodynamic diameter compared to the naked AuNPs. Also, as part of the characterization, differences in the UV-Vis absorbance spectrum and electrophoretic migration were observed between the conjugated AuNPs (with BSA or antibody) and naked AuNPs. Additionally, we used this biosensor (AuNP–4G2 conjugate with 3 µg/mL antibody) in the assembly of a competitive lateral flow assay (LFA) for the development of an alternative test to detect the flavivirus envelope protein in isolated DENV samples as a future tool for dengue detection (and other flaviviruses) in the mosquito vector (Aedesaegypti) for the identification of epidemic risk regions. Functionality tests were performed using Dengue virus 2 isolated solution (TCID50/mL = 4.58 × 103) as a positive sample and PBS buffer as a negative control. The results showed that it is possible to detect Dengue virus in vitro with this gold nanoparticle-based lateral flow assay with an estimated detection limit of 5.12 × 102 PFU. We suggest that this biosensor could be used as an additional detection tool by coupling it to different point-of-care tests (POCT) for the easy detection of other flaviviruses.

24 June 2021 in Viruses
Verified
Journal Article
Open access
PDF file
NMNatalia Martinez-Acuña
Natalia Martinez-Acuña
Diana Nolazco-AvalosDiana Nolazco-Avalos
Diana Nolazco-Avalos
DRDiana Raquel Rodríguez-Rodríguez
Diana Raquel Rodríguez-Rodríguez
CMCynthia Gabriela Martinez-Liu
Cynthia Gabriela Martinez-Liu
KGKame Galan-Huerta
Kame Galan-Huerta
ARAna M. Rivas-Estilla
Ana M. Rivas-Estilla
The progression and distribution of the SARS-CoV-2 pandemic are continuously changing over time and can be traced by blood donors’ serological survey. Here, we investigated the seroprevalence of anti-SARS-CoV-2 antibodies in blood donors in Nuevo Leon, Mexico during 2020 as a strategy for the rapid evaluation of the spread of SARS-CoV-2 and asymptomatic case detection. We collected residual plasma samples from blood donors who attended two regional donation centers from January to December of 2020 to identify changes in anti-SARS-CoV-2 IgG prevalence. Plasma samples were analyzed on the Abbott Architect instrument using the commercial Abbott SARS-CoV-2 IgG chemiluminescent assay. We found a total of 99 reactive samples from 2068 analyzed plasma samples, resulting in a raw prevalence of 4.87%. Donors aged 18–49 years were more likely to be seropositive compared to those aged >50 years (p < 0.001). Weekly seroprevalence increased from 1.8% during the early pandemic stage to 27.59% by the end of the year. Prevalence was 1.46-fold higher in females compared to males. Case geographical mapping showed that Monterrey city recorded the majority of SARS-CoV-2 cases. These results show that there is a growing trend of seroprevalence over time associated with asymptomatic infection that is unnoticed under the current epidemiological surveillance protocols.

14 January 2021 in Diagnostics
Verified
Journal Article
Open access
PDF file
AEAna María Rivas Estilla
Ana María Rivas Estilla
NMNatalia Martinez-Acuña
Natalia Martinez-Acuña
DADaniel Arellanos-Soto
Daniel Arellanos-Soto
KGKame Galan-Huerta
Kame Galan-Huerta
SSSonia Lozano Sepulveda
Sonia Lozano Sepulveda
ARAna M. Rivas-Estilla
Ana M. Rivas-Estilla
The new coronavirus that was first identified in December 2019 in Wuhan China, now called SARS-CoV-2, which causes the disease called COVID-19, has spread from China to the entire world in a few months. Due to its contagious potential (R0: 5.7) and because there is still no effective treatment to stop the infection, and a vaccine for prevention it is not yet available to the general population, COVID-19 is currently considered a global health problem. The need to implement sensitive methods for the identification of individuals with COVID-19 has led to the development of different molecular and immunological tests. The importance of a timely and accurate diagnosis is essential to determine the course of the pandemic. The interpretation of the results obtained by each test as well as the factors that affect these results have not been fully described. In this review, we describe and analyze the different SARS-CoV-2 detection methods that have been performed in Mexico and are available worldwide, outlining their strengths and weaknesses. Further, a broader perspective of the correct use and interpretation of the results obtained with these diagnostic tools is proposed to improve the containment strategy and identify the true impact of the pandemic.